What is the role of renin inhibition in the treatment of diabetic kidney disease?

Radko Komers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Inhibition of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in preventing and treating diabetic nephropathy. However, despite documented beneficial effects of RAAS inhibitors in diabetic patients with nephropathy, reversal of the progressive course of this disorder or at least long-term stabilization of renal function are often difficult to achieve, and many patients still progress to end-stage renal disease. Incomplete inhibition of the RAAS has been postulated as one of the reasons for unsatisfactory therapeutic responses to RAAS inhibition in some patients. Inhibition of renin, a rate-limiting step in the RAAS activation cascade, is the logical approach to overcome at least some of the above-mentioned problems associated with the treatment with traditional RAAS inhibitors. This article focuses on experimental and clinical studies evaluating the two principal approaches to renin inhibition: direct renin inhibition with competitive inhibitors (eg, aliskiren) and inhibition of the (pro)renin receptor.

Original languageEnglish (US)
Pages (from-to)447-452
Number of pages6
JournalCurrent Diabetes Reports
Volume9
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Diabetic Nephropathies
Renin-Angiotensin System
Renin
Therapeutics
Chronic Kidney Failure
Kidney

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

What is the role of renin inhibition in the treatment of diabetic kidney disease? / Komers, Radko.

In: Current Diabetes Reports, Vol. 9, No. 6, 12.2009, p. 447-452.

Research output: Contribution to journalArticle

@article{16ec7b8742e94aa382e4b4f26bd1b712,
title = "What is the role of renin inhibition in the treatment of diabetic kidney disease?",
abstract = "Inhibition of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in preventing and treating diabetic nephropathy. However, despite documented beneficial effects of RAAS inhibitors in diabetic patients with nephropathy, reversal of the progressive course of this disorder or at least long-term stabilization of renal function are often difficult to achieve, and many patients still progress to end-stage renal disease. Incomplete inhibition of the RAAS has been postulated as one of the reasons for unsatisfactory therapeutic responses to RAAS inhibition in some patients. Inhibition of renin, a rate-limiting step in the RAAS activation cascade, is the logical approach to overcome at least some of the above-mentioned problems associated with the treatment with traditional RAAS inhibitors. This article focuses on experimental and clinical studies evaluating the two principal approaches to renin inhibition: direct renin inhibition with competitive inhibitors (eg, aliskiren) and inhibition of the (pro)renin receptor.",
author = "Radko Komers",
year = "2009",
month = "12",
doi = "10.1007/s11892-009-0073-y",
language = "English (US)",
volume = "9",
pages = "447--452",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - What is the role of renin inhibition in the treatment of diabetic kidney disease?

AU - Komers, Radko

PY - 2009/12

Y1 - 2009/12

N2 - Inhibition of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in preventing and treating diabetic nephropathy. However, despite documented beneficial effects of RAAS inhibitors in diabetic patients with nephropathy, reversal of the progressive course of this disorder or at least long-term stabilization of renal function are often difficult to achieve, and many patients still progress to end-stage renal disease. Incomplete inhibition of the RAAS has been postulated as one of the reasons for unsatisfactory therapeutic responses to RAAS inhibition in some patients. Inhibition of renin, a rate-limiting step in the RAAS activation cascade, is the logical approach to overcome at least some of the above-mentioned problems associated with the treatment with traditional RAAS inhibitors. This article focuses on experimental and clinical studies evaluating the two principal approaches to renin inhibition: direct renin inhibition with competitive inhibitors (eg, aliskiren) and inhibition of the (pro)renin receptor.

AB - Inhibition of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in preventing and treating diabetic nephropathy. However, despite documented beneficial effects of RAAS inhibitors in diabetic patients with nephropathy, reversal of the progressive course of this disorder or at least long-term stabilization of renal function are often difficult to achieve, and many patients still progress to end-stage renal disease. Incomplete inhibition of the RAAS has been postulated as one of the reasons for unsatisfactory therapeutic responses to RAAS inhibition in some patients. Inhibition of renin, a rate-limiting step in the RAAS activation cascade, is the logical approach to overcome at least some of the above-mentioned problems associated with the treatment with traditional RAAS inhibitors. This article focuses on experimental and clinical studies evaluating the two principal approaches to renin inhibition: direct renin inhibition with competitive inhibitors (eg, aliskiren) and inhibition of the (pro)renin receptor.

UR - http://www.scopus.com/inward/record.url?scp=72849117722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849117722&partnerID=8YFLogxK

U2 - 10.1007/s11892-009-0073-y

DO - 10.1007/s11892-009-0073-y

M3 - Article

C2 - 19954690

AN - SCOPUS:72849117722

VL - 9

SP - 447

EP - 452

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 6

ER -